Fredun Pharmaceuticals Limited (FREDUN) Fair Value & Analysis
Healthcare · IN · Market cap ₹14.2B
Fair value as of: Jul 5, 2026
From 14 valuation models · updated today
Share price +11.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹806.62 – ₹2,814 · fair‑value band ₹1,775 – ₹3,296 · the ₹2,589 price screens above the ₹2,535 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Fredun Pharmaceuticals Limited (FREDUN) currently trades at ₹2,589, while our model-based Fair Value estimate is ₹2,535 — implying the stock looks roughly 2.1% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Fredun Pharmaceuticals Limited generated revenue of ₹6.4B at a net margin of 5.1%. Revenue grew 26.9% year over year. It earns a return on equity of 15.6%. Net debt stands at ₹1.6B. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹1,775 (bear case) to ₹3,296 (bull case); at ₹2,589, the current price sits within that range. The share trades about 10% below its 52-week high and 226% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside — at -2%, FREDUN screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, CIS countries, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It provides surgical products, such as IV fluids and cannula, disposable syringes, infusion sets, surgical gloves and cottons, and personal healthcare products; …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Fredun Pharmaceuticals Limited reported revenue of ₹6.3B in FY2025 versus ₹2.2B in FY2021, a compound +30.0%/yr. Reported net income was ₹326M in FY2025, compounding +50.6%/yr from FY2021.
Is FREDUN fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹991.46 | -47% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Fredun Pharmaceuticals Limited (FREDUN) undervalued?
What is the fair value of FREDUN?
What is the quality score of FREDUN?
What is the revenue of Fredun Pharmaceuticals Limited (FREDUN)?
What is the net profit margin of FREDUN?
Does Fredun Pharmaceuticals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.